• Technology
  • Applications
    • AML – MRD
    • Mutagenesis
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact
TwinStrand Biosciences
  • Technology
  • Applications
    • AML – MRD
    • Mutagenesis
    • Collaborate
  • Resources
    • Publications
    • Posters
    • Safety
    • Patents
  • Company
    • Our Team
    • Careers
    • Events
    • News
  • Contact

 

In the News

 

PRNewswire - January 6, 2021
TwinStrand Biosciences Appoints Dr. Gary Gilliland to Board of Directors

Dr. Gary Gilliland, MD, PhD, has been appointed to TwinStrand Biosciences’ Board of Directors as the company’s fifth board member. Dr. Gilliland brings over 30 years of clinical and research leadership experience, most recently serving as president and director of the Seattle-based Fred Hutchinson Cancer Research Center from 2015 to February 2020. “I am incredibly impressed with the work Dr. Salk and his team are doing to advance the field of DNA sequencing with their innovative Duplex Sequencing technology, which empowers clinicians and researchers to make decisions with previously unthinkable levels of accuracy,” said Dr. Gilliland. “I look forward to working with the TwinStrand team to fully realize the technology’s many applications in the clinic and beyond.”

Read More
X
TwinStrand Biosciences Appoints Dr. Gary Gilliland to Board of Directors
GenomeWeb - January 6, 2021
TwinStrand Biosciences Explores Error Reduction Sequencing Tech in Various Applications
Read More
PRNewswire - January 6, 2021
TwinStrand Biosciences Appoints Dr. Gary Gilliland to Board of Directors
Read More
PRNewswire - December 15, 2020
TwinStrand Biosciences Announces Peer-Reviewed Publication of Study Results Highlighting Ability of Duplex Sequencing Technology to Rapidly Detect the Mutagenic Activity of Chemicals
Read More
PRNewswire - November 18, 2020
TwinStrand Biosciences Licenses Duplex Sequencing Technology to Foundation Medicine
Read More
Puget Sound Business Journal - October 1, 2020
40 Under 40: Jesse Salk diagnoses cancer using DNA sequencing and treats the disease as a practicing oncologist
Read More
GEN - August 1, 2020
Liquid Biopsies Generate Ample Insights from Sparse Clues
Read More
Gene Online - July 20, 2020
The Profound Impact of Duplex Sequencing: An Interview with Jesse Salk, CEO, TwinStrand Biosciences
Read More
Bio-IT World - July 15, 2020
In The Midst Of A Pandemic, Duplex Sequencing Comes Of Age
Read More
Timmerman Report - June 15, 2020
Timmerman Report- DNA Sequencing Startups Aim to Reduce Cost, Increase Meaning in the Data
Read More
GEN - April 1, 2020
Sequencing’s Stars Urge Exploration of New Dimensions
READ MORE
GEN - March 1, 2020
Genomic Medicine Identifies Reconcilable Differences
Read More
DeciBio - February 27, 2020
AGBT 2020: DeciBio Highlights – Spatial Profiling Reloaded & MGI Unleashed 2
Read More
PRNewswire - February 25, 2020
TwinStrand Biosciences Launches Duplex Sequencing Technology
Read More
GeekWire - January 7, 2020
TwinStrand raises $16M from Madrona and others for next-gen DNA sequencing, promising early cancer detection and other breakthroughs
Read More
LinkedIn - January 7, 2020
Leveraging big data to improve genome sequencing accuracy by 10,000x
Read More

 

TwinStrand Biosciences, Inc.
3131 Elliott Ave, Suite 750 • Seattle, WA 98121 • USA
+1 (877) 202-TWIN

 

For Research Use Only. Not for use in diagnostic procedures.

©2020 TwinStrand Biosciences, Inc. All rights reserved. All trademarks are the property of TwinStrand Biosciences, Inc. or their respective owners.  Legal Notices

  

This website uses cookies to improve your experience. Read More. You can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

American Society of Hematology (ASH)

December 5-8, 2020 – Virtual

 

Poster Presentation

 

“Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia”

 

Presented by Jake Higgins, Senior Scientist – December 6, 2020 7:00 a.m.-3:30 p.m. PST

 

Conference Website

 

Society of Toxicology (SOT)

March 10-14, 2019 – Baltimore, MD

 

Poster Presentations

 

 

View Poster

 

 

Conference Website

 

AACR Annual Meeting – San Diego, CA

March 29-April 3, 2019

 

Poster Presentations

 

 

View Poster

 

 

View Poster

Presentations by CEO Jesse Salk, MD, PhD – AGBT 2020

Ultra-Sensitive Residual Leukemia Detection with Patient-Specific Dupex Sequencing